Abstract

Here, we have unveiled the effects of cycloastragenol against Aβ (Amyloid-beta)-induced oxidative stress, neurogenic dysfunction, activated mitogen-activated protein (MAP) kinases, and mitochondrial apoptosis in an Aβ-induced mouse model of Alzheimer’s disease (AD). The Aβ-induced mouse model was developed by the stereotaxic injection of amyloid-beta (5 μg/mouse/intracerebroventricular), and cycloastragenol was given at a dose of 20 mg/kg/day/p.o for 6 weeks daily. For the biochemical analysis, we used immunofluorescence and Western blotting. Our findings showed that the injection of Aβ elevated oxidative stress and reduced the expression of neurogenic markers, as shown by the reduced expression of brain-derived neurotrophic factor (BDNF) and the phosphorylation of its specific receptor tropomyosin receptor kinase B (p-TrKB). In addition, there was a marked reduction in the expression of NeuN (neuronal nuclear protein) in the Aβ-injected mice brains (cortex and hippocampus). Interestingly, the expression of Nrf2 (nuclear factor erythroid 2–related factor 2), HO-1 (heme oxygenase-1), p-TrKB, BDNF, and NeuN was markedly enhanced in the Aβ + Cycloastragenol co-treated mice brains. We have also evaluated the expressions of MAP kinases such as phospho c-Jun-N-terminal kinase (p-JNK), p-38, and phospho-extracellular signal-related kinase (ERK1/2) in the experimental groups, which suggested that the expression of p-JNK, p-P-38, and p-Erk were significantly upregulated in the Aβ-injected mice brains; interestingly, these markers were downregulated in the Aβ + Cycloastragenol co-treated mice brains. We also checked the expression of activated microglia and inflammatory cytokines, which showed that cycloastragenol reduced the activated microglia and inflammatory cytokines. Moreover, we evaluated the effects of cycloastragenol against mitochondrial apoptosis and memory dysfunctions in the experimental groups. The findings showed significant regulatory effects against apoptosis and memory dysfunction as revealed by the Morris water maze (MWM) test. Collectively, the findings suggested that cycloastragenol regulates oxidative stress, neurotrophic processes, neuroinflammation, apoptotic cell death, and memory impairment in the mouse model of AD.

Highlights

  • Introduction conditions of the Creative CommonsAlzheimer’s is a neurodegenerative disorder linked with cognitive and memory dysfunction, other clinical symptoms are recognized

  • A reported mechanism for the pathogenic role of oxidative stress in the execution of neurodegeneration is the suppression of nuclear factor erythroid-2 related factor-2 (NRF2), which upon binding with antioxidant genes activates a plethora of cytoprotective genes against elevated oxidative insult [3,4]

  • According to the Western blotting results, Aβ markedly reduced the expression of Nrf2 and HO-1 compared to the saline-injected control group

Read more

Summary

Introduction

Introduction conditions of the Creative CommonsAlzheimer’s is a neurodegenerative disorder linked with cognitive and memory dysfunction, other clinical symptoms are recognized. Some known factors that play a role in the neurogenic processes are tropomyosin-receptor kinase B (TrKB), brain-derived neurotrophic factor (BDNF), and cAMP-response element-binding protein (CREB). The critical effects of BDNF are developmental processes, synaptogenesis, neuroprotection, and the control of synaptic interactions that affect memory and cognitive functions [12,13]. Another main factor in the memory and neuronal cells’ survival is CREB, which is known for the formation of cognitive and memory functions [14]. It has been reported that the dysfunction of the CREB signaling in AD mouse models [16,17]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call